UCB S.A.

Industry

  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Drug Discovery Technologies
      • Bioinformatics
      • Genomics-Proteomics
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Research, Analytical Equipment & Supplies

Other Names/Subsidiaries

  • Celltech Pharmaceutical
  • Element Genomics
  • Engage Therapeutics
  • Handl Therapeutics
  • Meizler Biopharma
  • Ra Pharmaceuticals
  • Schwarz Pharma
  • UCB Biopharma
  • Upstate Pharma
  • Zogenix
See more in Biomedtracker

Latest on UCB S.A.

Scrip

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

UCB has become the latest Europe drugmaker to pledge major manufacturing investments in the US amid the pressure being put on the pharmaceutical sector by President Trump administration to move more d

Scrip

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

SpliceBio already had the backing from the venture arms of two pharma companies – UCB and Novartis – and two other big players in the industry have participated in an impressive second funding round f

Scrip

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

US/Swiss biotech GlycoEra AG announced a $130m series B financing on 27 May that it says will enable it to advance its first protein-degradation drug candidate through Phase II proof of concept as pre

Scrip

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

Merck KGaA is pursuing a Phase III program for its novel toll-like receptor 7/8 inhibitor enpatoran in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE), despite